Everyone loves a dark horse story. Biotech, however, is one of the hardest arenas for spotting these overlooked contenders. Because therapeutic development is so capital-intensive, investors must make massive commitments years before pivotal clinical trials occur, long before it’s clear which technology will prevail. Within the cell therapy space specifically, investors are tracking a crucial […]
